drugset
drugset / Trial / NCT04561128

A Trial of SHR-1819 in Healthy Subjects

NCT04561128 ↗

Phase 1 Completed 42 enrolled Atridia Pty Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a single center, randomized, double-blind, placebo-controlled, single dose escalation phase 1 study.

Timeline

Start
2020-11-01
Primary completion
2022-03-07
Completion
2022-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1819 Monoclonal antibody — Subcutaneous

Indications

No indication recorded.